5YL Stock Chart & Stats
€0.04
>-€0.01(-4.00%)
At close: 4:00 PM EDT
€0.04
>-€0.01(-4.00%)
Day’s Range― - ―
52-Week Range€0.02 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€30.00M
Enterprise Value€268.87
Total Cash (Recent Filing)€43.09M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Nov 11, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding394,878,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.85
Price to Sales (P/S)4.14
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€3.71M
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthA return to double-digit trailing revenue growth indicates improving commercial traction and product adoption. Sustained top-line expansion could strengthen operating leverage if BrainCool converts demand into better margins.
Debt-free Balance SheetZero debt materially limits interest burden and refinancing risk, giving BrainCool greater flexibility to fund commercialization. The sizable equity base provides a buffer while management works to improve profitability and cash generation.
Recurring Consumables ModelA system-and-consumables model can create repeat revenue from each hospital installation as treatments consume single-use products. Over time, a larger installed base may improve revenue visibility and customer retention.
Bears Say
Persistent UnprofitabilityNegative gross profit and substantial operating losses show that current revenue does not yet support a viable scalable profit model. Without sustained margin improvement, growth may increase resource needs rather than strengthen financial performance.
Heavy Cash BurnCash outflows of this scale relative to the business indicate that losses are translating into real funding needs, not merely accounting charges. Persistent burn could require financing and constrain investment in sales, development, and operations.
Negative Returns And Dilution RiskA negative return on equity indicates that the capital base is not currently producing economic returns. If profitability remains weak, continued funding requirements may erode equity value or lead to dilution for existing shareholders.
BrainCool AB News
5YL FAQ
What was BrainCool AB’s price range in the past 12 months?
BrainCool AB lowest stock price was €0.02 and its highest was €0.09 in the past 12 months.
What is BrainCool AB’s market cap?
BrainCool AB’s market cap is €30.00M.
When is BrainCool AB’s upcoming earnings report date?
BrainCool AB’s upcoming earnings report date is Nov 11, 2026 which is in 73 days.
How were BrainCool AB’s earnings last quarter?
BrainCool AB released its earnings results on Aug 12, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of €0 by €0.
Is BrainCool AB overvalued?
According to Wall Street analysts BrainCool AB’s price is currently Overvalued.
Does BrainCool AB pay dividends?
BrainCool AB does not currently pay dividends.
What is BrainCool AB’s EPS estimate?
BrainCool AB’s EPS estimate is 0.
How many shares outstanding does BrainCool AB have?
BrainCool AB has 394,878,140 shares outstanding.
What happened to BrainCool AB’s price movement after its last earnings report?
BrainCool AB reported an EPS of €0 in its last earnings report, expectations of €0. Following the earnings report the stock price went down -8%.
Which hedge fund is a major shareholder of BrainCool AB?
Currently, no hedge funds are holding shares in DE:5YL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BrainCool AB
BrainCool AB (publ), a medical technology company founded in 2010 and headquartered in Lund, Sweden, focuses on the development, commercialization, and distribution of advanced medical cooling systems. Operating with its subsidiaries, the company caters to the healthcare sector, primarily serving the Swedish market, by providing innovative solutions for various conditions including stroke, sudden cardiac arrest, oral mucositis, and migraine. Their product line features the BrainCool and RhinoChill systems, specifically engineered to deliver swift therapeutic cooling in emergency situations, thereby ensuring uninterrupted patient care. To mitigate the risk of oral mucositis, BrainCool offers the Cooral system, renowned for its user-friendly design for medical professionals. Furthermore, the IQool system boasts an intuitive interface complemented by informative graphics and an automatic feedback loop, empowering clinicians to dedicate their attention to patient management rather than device operation.